|Assessment Status||Assessment Process Complete|
|Indication||For the treatment of mild to moderate idiopathic pulmonary fibrosis.|
|Rapid review commissioned||15/12/2011|
|Rapid review completed||05/01/2012|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
|Full submission received from Applicant||26/11/2012|
|NCPE assessment completed||20/03/2013|
|NCPE assessment outcome||Reimbursement not Recommended|
The NCPE believe that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis.
The HSE has approved reimbursement following confidential price negotiations March 2015.